

# **The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells**

**Daniela Frezzetti <sup>1</sup>, Vincenza Caridi <sup>1</sup>, Laura Marra <sup>1</sup>, Rosa Camerlingo <sup>1</sup>, Amelia D'Alessio <sup>2</sup>, Francesco Russo <sup>3</sup>, Serena Dotolo <sup>1</sup>, Anna Maria Rachiglio <sup>1</sup>, Riziero Esposito Abate <sup>1</sup>, Marianna Gallo <sup>1</sup>, Monica Rosaria Maiello <sup>1</sup>, Alessandro Morabito <sup>4</sup>, Nicola Normanno <sup>1,\*</sup> and Antonella De Luca <sup>1</sup>**

## **Table of contents**

<b>Supplementary Methods.....</b>	<b>Page 2</b>
<b>Supplementary Tables.....</b>	<b>Pages 3</b>
<b>Supplementary Figures.....</b>	<b>Pages 4-9</b>

## **Supplementary Methods**

### *Cell proliferation assay*

HCC827 and PC9 parental and gefitinib resistant (GR) cells ( $2 \times 10^3$  cells/well and  $6 \times 10^2$  cells/well, respectively) were seeded in 96-well plates in gefitinib-free medium. Cell proliferation was determined by tetrazolium-based (MTT) colorimetric assay according to standard procedures.


## Supplementary Tables

**Table S1:** List of genes analysed by targeted sequencing


Hot spot genes	Full-length genes	Copy number genes	Gene fusions
AKT1 AKT2 AKT3 ALK AR ARAF	ARID1A ATM ATR ATRX BAP1	AKT1 AKT2 AKT3 ALK	AKT2 ALK AR AXL
AXL BRAF BTK CBL CCND1	BRCA1 BRCA2 CDK12	AXL AR BRAF CCND1	BRCA1 BRCA2 BRAF
CDK4 CDK6 CHEK2 CSF1R	CDKN1B CDKN2A CDKN2B	CCND2 CCND3 CCNE1	CDKN2A EGFR ERBB2
CTNNB1 DDR2 EGFR ERBB2	CHEK1 CREBBP FANCA	CDK2 CDK4 CDK6 EGFR	ERBB4 ERG ESR1 ETV1
ERBB3 ERBB4 ERCC2 ESR1 EZH2	FANCD2 FANCI FBXW7 MLH1	ERBB2 ESR1 FGF19 FGF3	ETV4 ETV5 FGFR1 FGFR2
FGFR1 FGFR2 FGFR3 FGFR4 FLT3	MRE11 MSH6 MSH2 NBN NF1	FGFR1 FGFR2 FGFR3	FGFR3 FGR FLT3 JAK2
FOXL2 GATA2 GNA11 GNAQ	NF2 NOTCH1 NOTCH2	FGFR4 FLT3 IGF1R KIT	KRAS MDM4 MET MYB
GNAS H3F3A HIST1H3B HNF1A	NOTCH3 PALB2 PIK3R1 PMS2	KRAS MDM2 MDM4 MET	MYBL1 NF1 NOTCH1
HRAS IDH1 IDH2 JAK1 JAK2	POLE PTCH1 PTEN RAD50	MYC MYCL MYCN NTRK1	NOTCH4 NRG1 NTRK1
JAK3 KDR KIT KNSTRN KRAS	RAD51 RAD51B RAD51C	NTRK2 NTRK3 PDGFRA	NTRK2 NTRK3 NUTM1
MAGOH MAP2K1 MAP2K2	RAD51D RNF43 RB1 SETD2	PDGFRB PIK3CB PIK3CA	PDGFRA PDGFRB
MAP2K4 MAPK1 MAX MDM4	SLX4 SMARCA4 SMARCB1	PPARG RICTOR TERT	PIK3CA PRKACA
MED12 MET MTOR MYC MYCN	STK11 TP53 TSC1 TSC2		PRKACB PTEN PPARG
MYD88 NFE2L2 NRAS NTRK1			RAD51B RAF1 RB1 RELA
NTRK2 NTRK3 PDGFRA			RET ROS1 RSPO2 RSPO3
PDGFRB PIK3CB PIK3CA			TERT
PPP2R1A PTPN11 RAC1 RAF1			
RET RHEB RHOA ROS1 SF3B1			
SMAD4 SMO SPOP SRC STAT3			
TERT TOP1 U2AF1 XPO1			

**Table S2:** List of all differentially expressed genes (DEGs) identified in GR cell lines. The content of the table is available as a separate file.


## Supplementary Figures




**Figure S1:** Cell proliferation of gefitinib resistant (GR) NSCLC cells. Parental and GR cells were grown in gefitinib-free medium. Cell proliferation was measured at the indicated time points by MTT assay.




**Figure S2:** Transcriptome analysis of GR cells. RNA-Seqheatmaps showing genes differentially expressed between GR and relative parental cells. Expression data are shown in duplicate for each cell line.



**Figure S3:** Analysis of differentially expressed genes (DEGs) in GR cells. Volcano plots showing DEGs in GR cells relative to parental cells. The number of statistically significant downregulated and upregulated DEGs is indicated in bold (adjusted p-value  $< 0.05$ ). Abbreviations: Padj: adjusted p-value; FC: Fold Change.



(a)




(b)


**Figure S4:** Analysis of migration in GR cells. (a) Representative images of wound healing assay at the indicated time points are shown for parental and GR cells. (b) Representative images of wound healing assay at the indicated time points performed on HCC827 parental and GR-Low cells, untreated and treated with LY2109761 (LY, 5  $\mu$ M).

### Raw data Figure 2c


#### HCC827



### Raw data Figure 2a




### Raw data Figure 2b




**Figure S5.** Original immunoblot images of figures 2a, b and c. The original scans of the blots are shown. Squares indicate the images used for final figures.

## Raw Data Figure 2d

**PC9**




## Raw Data Figure 5a



**Figure S6.** Original immunoblot images of figures 2d and 5a. The original scans of the blots are shown. Squares indicate the images used for final figures.

**Raw data Figure 6a**



**Figure S7.** Original microscopy images of figure 6a. The original images obtained with fluorescence microscope are shown.